| Date Filed | Type | Description |
| 10/03/2023 |
4
| Chen Hubert C (See remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 2,593 shares
@ $0.662, valued at
$1.7k
Exercised 7,500 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| Riley Antony A (CFO) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 3,241 shares
@ $0.662, valued at
$2.1k
Exercised 9,375 restricted stock units
@ $0 |
|
| 10/03/2023 |
4
| Wagner Paul A. (See Remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 2,453 shares
@ $0.662, valued at
$1.6k
Exercised 31,250 restricted stock units
@ $0 |
|
| 09/26/2023 |
8-K/A
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/25/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 08/25/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 08/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/24/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 08/23/2023 |
SC 13D
| Camac Fund, LP reports a 4.3% stake in Forte Biosciences, Inc. |
| 08/17/2023 |
PRRN14A
| Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise: |
| 08/15/2023 |
SC 13D/A
| Wagner Paul A. reports a 5.2% stake in Forte Biosciences, Inc. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 8.2% stake in Forte Biosciences, Inc. |
| 08/10/2023 |
SC 13G
| Farallon Capital Partners, L.P. reports a 9.9% stake in Forte Biosciences, Inc. |
| 08/10/2023 |
SC 13D/A
| ATG Fund II LLC reports a 4% stake in Forte Biosciences, Inc. |
| 08/09/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/04/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/03/2023 |
SC 13D/A
| Camac Fund, LP reports a 3.6% stake in Forte Biosciences Inc. |
| 08/02/2023 |
4
| Kornfeld Steven (Director) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Granted 99,009 shares
@ $1.01, valued at
$100k
|
|
| 08/02/2023 |
4
| Williams Donald Allen (Director) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Granted 59,405 shares
@ $1.01, valued at
$60k
|
|
| 08/02/2023 |
4
| GRYSKA DAVID W (Director) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Granted 148,514 shares
@ $1.01, valued at
$150k
|
|
| 08/02/2023 |
4
| Chen Hubert C (See remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Granted 74,257 shares
@ $1.01, valued at
$75k
|
|
| 08/02/2023 |
4
| Riley Antony A (CFO) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Granted 148,514 shares
@ $1.01, valued at
$150k
|
|
| 08/02/2023 |
4
| Wagner Paul A. (See Remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Granted 247,524 shares
@ $1.01, valued at
$250k
|
|
| 08/02/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/06/2023 |
SC 13D/A
| Funicular Funds, LP reports a 9.6% stake in Forte Biosciences, Inc. |
| 07/05/2023 |
SC 13D/A
| Camac Fund, LP reports a 8.6% stake in Forte Biosciences Inc. |
| 07/05/2023 |
4
| Chen Hubert C (See remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 2,593 shares
@ $1.04, valued at
$2.7k
Exercised 7,500 restricted stock units
@ $0 |
|
| 07/05/2023 |
4
| Riley Antony A (CFO) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 3,241 shares
@ $1.04, valued at
$3.4k
Exercised 9,375 restricted stock units
@ $0 |
|
| 07/05/2023 |
4
| Wagner Paul A. (See Remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 2,453 shares
@ $1.04, valued at
$2.6k
Exercised 31,250 restricted stock units
@ $0 |
|
| 05/25/2023 |
PREC14A
| Form PREC14A - Preliminary proxy statements, contested solicitations: |
| 05/25/2023 |
SC 13D/A
| Camac Fund, LP reports a 8.6% stake in Forte Biosciences Inc. |
| 04/04/2023 |
4
| Wagner Paul A. (See Remarks) has filed a Form 4 on Forte Biosciences, Inc.|
Txns:
| Paid exercise price by delivering 11,046 shares
@ $1.01, valued at
$11.2k
Exercised 31,250 restricted stock units
@ $0 |
|
|